Atezolizumab Combo Approved for Frontline Treatment of Metastatic Non-Small Cell Lung Cancer
December 7th 2018Atezolizumab (Tecentriq) approved by FDA in combination with bevacizumab (Avastin), carboplatin, and paclitaxel for the first-line treatment of metastatic nonsquamous non-small cell lung cancer.
Read More